Mark A. Hallman, MD, PhD
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111
Video: Mark Hallman, MD, PhD
My primary role is as a member of the thoracic oncology program treating lung cancer, mesothelioma and cancers of the thymus. I also treat genitourinary cancers including prostate cancer, bladder cancer, and testicular cancer. In addition I treat lymphoma and leukemia as a member of the hematologic malignancy program.
I have had extensive training in several specialized radiation techniques:
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)
- Prostate Brachytherapy
American Board of Radiology,
I earned doctorate degrees in both medicine and pharmacology research at the Medical University of South Carolina enrolled in the Medical Scientist Training Program. After graduation I joined Fox Chase Cancer Center for my medical residency training in the Department of Radiation Oncology. Upon completing residency I was recruited to become a member of the department faculty treating thoracic cancers, genitourinary cancers, and hematologic cancers. As part of that role, I will also be conducting research and designing clinical trials to both improve upon our current treatments and to develop new technologies in the fight against cancer.
While knowledge and expertise are important, I believe that compassion and personalized care are also essential to being an effective physician. I strive to establish trust and understanding with my patients in order to best help them complete complex and intense cancer therapies in order to achieve the best possible outcomes.
This is an exciting time to be at Fox Chase Cancer Center. The faculty and staff at Fox Chase work as a team with the common goal of providing world class cancer treatment. Not only do I have access to state of the art technologies and cutting-edge treatments, but I also have the opportunity to develop new treatments that will improve the way we treat cancer in the future.
M.D., Ph.D. in Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, 2009
Department of Radiation Oncology
Fox Chase Cancer Center, Philadelphia, PA, 2014
Professional SocietiesAmerican Society for Therapeutic Radiology and Oncology
Association of Residents in Radiation Oncology
American Society of Clinical Oncology
Radiological Society of North America
My research has focused on improving the safety and efficacy of delivering SBRT. I will also focus on developing new ways to deliver radiation treatments to cancers that are otherwise untreatable with conventional therapies. These methods will use exciting new drug and radiation combinations to enhance the effects and targeting of radiation on tumor cells.
- Effects of active and inactive phospholipase 02 011 sig11GI transductio11, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells.
Knoepp SM, Chahal MS, Xie Y, Zhang Z, Brauner DJ, Hallman MA, Robinson SA, Han S, Imai M, Tomlinson S, Meier KE. Mal Pharma col, 2008 Sep;74(3):574-84.
- Regulation af dedifferentiation and redifferentiation in renal proximal tubular cells by the epidermal growth factor receptor.
Hallman MA, Zhuang S, Schnellmann RG.
J Pharmacol Exp Ther, 2008 May;325(2):520-8.
- RasGRP1 confers the phorbol ester-sensitive phenotype to EL4 lymphoma cells.
Han S, Knoepp SM, Hallman MA, Meier KE, Mol Pharmacol. 2007 Jan;71(1):314-22.
- Effect of antioxida11ts 011 para-aminophenol-induced toxicity in LLC-PKl cells.
Hallman MA, Tcaho R, Tarloff JB.
Toxicology, 2000 Dec 7;156(1):37-45.
- Prostate, In: Radiation Oncology - Imaging and Treatment 1st ed, Ed: Gaffney DK, Amirsys, 2013, Section 6, p 54-79
Hallman MA and Buyyounouski MB
- Dedifferentiation and Redifferentiation in Epithelial Repair, In: Comprehensive Toxicology 2°' ed, Ed: McQueen CA, Elsevier, Oxford, 2010, p 151-167
Hallman MA and Schnellmann RG.